ERBB2 and cancer: Group 2 had higher missing rates in terms of cancer stage (12.2% vs 3.1%) and HER2 status (15.1% vs 11.0%), whereas group 1 had more missing data for lesion size (20.5% vs 5.9%) and lymph node assessment (21.5% vs 8.8%).